These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 21558619)
21. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222 [TBL] [Abstract][Full Text] [Related]
23. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217 [TBL] [Abstract][Full Text] [Related]
24. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Markatseli TE; Kaltsonoudis ES; Voulgari PV; Zioga A; Drosos AA Clin Exp Rheumatol; 2009; 27(6):996-8. PubMed ID: 20149320 [TBL] [Abstract][Full Text] [Related]
25. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852 [TBL] [Abstract][Full Text] [Related]
26. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. Renato GM Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222 [TBL] [Abstract][Full Text] [Related]
27. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Pescovitz MD Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321 [TBL] [Abstract][Full Text] [Related]
28. B cells in rheumatoid arthritis: from hypothesis to the clinic. Keystone EC Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525 [TBL] [Abstract][Full Text] [Related]
29. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis]. Yukawa N; Mimori T Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487 [TBL] [Abstract][Full Text] [Related]
30. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases]. Tanaka Y Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410 [TBL] [Abstract][Full Text] [Related]
31. Rituximab treatment in rheumatoid arthritis: how does it work? Boumans MJ; Tak PP Arthritis Res Ther; 2009; 11(6):134. PubMed ID: 20017888 [TBL] [Abstract][Full Text] [Related]
32. Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. Vital EM; Dass S; Buch MH; Rawstron AC; Ponchel F; McGonagle D; Emery P Arthritis Rheum; 2009 Jun; 60(6):1867; author reply 1867-8. PubMed ID: 19479853 [No Abstract] [Full Text] [Related]
34. The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis. Gamonet C; Deschamps M; Marion S; Herbein G; Chiocchia G; Auger I; Saas P; Ferrand C; Toussirot E Rheumatology (Oxford); 2015 Sep; 54(9):1744-5. PubMed ID: 26117335 [No Abstract] [Full Text] [Related]
35. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989 [TBL] [Abstract][Full Text] [Related]
36. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453 [TBL] [Abstract][Full Text] [Related]
37. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414 [TBL] [Abstract][Full Text] [Related]
39. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens. Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777 [TBL] [Abstract][Full Text] [Related]
40. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Pers YM; Jorgensen C Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]